| Description | Glatiramer acetate (GA) is a synthetic amino acid copolymer that is approved for treatment of relapsing remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS). |
| In vivo | CAG140基因敲入和N171-82Q转基因小鼠组分别接受了GA（0.625 mg/只）治疗，直到CAG140小鼠达到1岁或N171-82Q小鼠达到20周。在整个治疗期间，通过各种行为测试评估了化合物治疗效果，结果显示，GA治疗能够推迟HD行为症状的出现并减轻其严重程度。GA的有益作用与提高I型和IV型启动子驱动的脑源性神经营养因子（Bdnf）表达水平以及减少HD小鼠大脑中的细胞因子水平，特别是白介素IL4和IL12的水平，有关。此外，GA对BDNF、IL4和IL12水平的影响也在接受化合物治疗的小鼠和大鼠的血浆中检测到，这表明它们可以作为治疗有效性的外周生物标志物。这些临床前研究支持使用GA作为HD患者的相关临床治疗方法[3]。 |
| molecular weight | 623.65 |
| Molecular formula | C25H45N5O13 |
| CAS | 147245-92-9 |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: Insoluble H2O: 10 mM |
| References | 1. Prod'homme T, Zamvil SS. The Evolving Mechanisms of Action of Glatiramer Acetate. Cold Spring Harb Perspect Med. 2019 Feb 1;9(2):a029249. doi: 10.1101/cshperspect.a029249. 2. McKeage K. Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review. CNS Drugs. 2015;29(5):425-432. 3. Arnon R, et al. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004;101 Suppl 2(Suppl 2):14593-14598. 4. Corey-Bloom J, et al. Beneficial effects of glatiramer acetate in Huntington's disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms. Brain Res. 2017;1673:102-110. |